Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Leukemia

Free Subscription 12.01.2026 3 Am J Hematol 5 Ann Hematol 3 Blood 1 Bone Marrow Transplant 1 Cancer 1 Cell 2 Leuk Lymphoma 1 Leuk Res 6 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. PRATZ KW, DiNardo CD, Arellano M, Thirman MJ, et al
   Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies.
   Am J Hematol. 2026 Jan 9. doi: 10.1002/ajh.70204.
   PubMed        
   
   
2. KONOPLEVA M, DiNardo CD, Sun Y, Jung P, et al
   Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine.
   Am J Hematol. 2026 Jan 5. doi: 10.1002/ajh.70161.
   PubMed        
   
   
3. NAGLER A, Kayser S, Ferhat AT, Kroger N, et al
   Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT.
   Am J Hematol. 2026;101:281-290.
   PubMed         Abstract available
   
   

   
   Ann Hematol

4. ZHANG X, Zhao Y, Zhai W, Ma Q, et al
   Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome?.
   Ann Hematol. 2025;104:6463-6466.
   PubMed         Abstract available
   
   
5. OSANNO L, Brocque L, Bourguignon L, Delpech C, et al
   Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.
   Ann Hematol. 2025;104:6327-6337.
   PubMed         Abstract available
   
   
6. TRINQUAND A, Betts DR, Rooney S, Storey L, et al
   Paediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland.
   Ann Hematol. 2025;104:6297-6304.
   PubMed         Abstract available
   
   
7. KHALIFA IM
   Richter's transformation: status quo and quo vadis.
   Ann Hematol. 2025;104:6117-6130.
   PubMed         Abstract available
   
   
8. SOHN C, Schafer-Eckart K, Wendelin K, Knop S, et al
   Early allogeneic stem cell transplantation after melphalan-induced aplasia leads to long-term survival in patients with primary refractory AML.
   Ann Hematol. 2025;104:6351-6358.
   PubMed         Abstract available
   
   

   
   Blood

9. SHARPE-DAVIDSON WF, Wan YO
   Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.
   Blood. 2026;147:215.
   PubMed        
   
   
10. DOHNER H, Spath D, Saadati M, Fiedler W, et al
    Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
    Blood. 2026 Jan 5:blood.2025030722. doi: 10.1182/blood.2025030722.
    PubMed         Abstract available
    
    
11. GUARNERA L, Wahida A, Gurnari C, Hutter S, et al
    Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.
    Blood. 2026;147:197-208.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

12. LOPEZ-PEREIRA P, Bazarbachi A, Marcais A, Ngoya M, et al
    Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.
    Bone Marrow Transplant. 2026 Jan 3. doi: 10.1038/s41409-025-02783.
    PubMed         Abstract available
    
    

    
    Cancer

13. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
    Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
    Cancer. 2026;132:e70243.
    PubMed         Abstract available
    
    

    
    Cell

14. LINKERMANN A
    When heme is low, copper kills cancer.
    Cell. 2026;189:3-5.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

15. HU GH, Zuo YX, Zhang XH, Wang Y, et al
    Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Jan 7:1-7. doi: 10.1080/10428194.2025.2611117.
    PubMed         Abstract available
    
    
16. GUO J, Li M, Zhang L, Zhang Q, et al
    Clinical outcomes of modified busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for T-cell acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2026 Jan 5:1-14. doi: 10.1080/10428194.2025.2605516.
    PubMed         Abstract available
    
    

    
    Leuk Res

17. STERN MA, Klekovkina E, Nanos SM, Fuller-Thomson E, et al
    Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia.
    Leuk Res. 2026 Jan 8:108154. doi: 10.1016/j.leukres.2025.108154.
    PubMed         Abstract available
    
    

    
    Leukemia

18. GONZALES F, Schneider C, Alexe G, Lin S, et al
    Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.
    Leukemia. 2026 Jan 8. doi: 10.1038/s41375-025-02845.
    PubMed         Abstract available
    
    
19. AGATHANGELIDIS A, Iatrou A, Pechlivanis N, Karakatsoulis G, et al
    Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.
    Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02797.
    PubMed        
    
    
20. AYOUB M, Hitier C, Dehgane L, Mallet E, et al
    Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.
    Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02846.
    PubMed        
    
    
21. FUJIMOTO A, Maeda T, Doki N, Fukuhara N, et al
    Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.
    Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02854.
    PubMed         Abstract available
    
    
22. GURNARI C, Makishima H, Durmaz A, Attardi E, et al
    DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
    Leukemia. 2026;40:178-187.
    PubMed         Abstract available
    
    
23. BILL M, Eckardt JN, Dohner K, Rohnert MA, et al
    Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
    Leukemia. 2026;40:63-71.
    PubMed         Abstract available
    
    

    
    PLoS One

24. DE ALMEIDA PM, Belas A, Nogueira P, Meneses A, et al
    Prevalence of feline leukemia virus infection and associated diseases in a Portuguese domestic cat population: A 4.5-year cross-sectional study.
    PLoS One. 2026;21:e0339172.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.